| Previous Close | 4.1000 |
| Open | 4.2000 |
| Bid | 0.0001 x 800 |
| Ask | 6.6400 x 1100 |
| Day's Range | 3.9000 - 4.2000 |
| 52 Week Range | 2.1800 - 8.4800 |
| Volume | 14,813 |
| Avg. Volume | 25,236 |
| Market Cap | 71.631M |
| Beta (3Y Monthly) | 0.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
LONDON and REDWOOD CITY, Calif., July 16, 2019 -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), a clinical stage biopharmaceutical company focused on rare diseases, today.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs June 12) • Abbott Laboratories (NYSE: ABT ) • Avedro ...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 29) Chiasma Inc (NASDAQ: CHMA ) Soliton Inc (NASDAQ: SOLY ...
Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage biopharmaceutical company focused on rare diseases, today announced encouraging 6 month data from the open label arm of its phase 2b dose-ranging clinical study in adults with Type I, III or IV osteogenesis imperfecta (OI) treated with BPS-804 (setrusumab), the “ASTEROID” Study (ClinicalTrials.gov Identifier: NCT03118570). The primary endpoint of the study is the percentage change over baseline in trabecular volumetric bone mineral density (Tr vBMD) of the radius (the wrist) at 12 months, assessed using High Resolution peripheral Quantitative Computed Tomography (HR-pQCT), with a hierarchial analysis of change over baseline in radius bone strength on Finite Element Analysis (FEA).
Mereo BioPharma Group plc (AIM: MPH, NASDAQ:MREO), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, today announces that the Trustee of the Mereo BioPharma Group plc Employee Benefit Trust (the “Trust”), Link Trustees (Jersey) Limited (the “Trustee”), has today indicated its intention to make market purchases of ordinary shares of the Company for the benefit of the Trust of up to £1,000,000 in aggregate amount, to help meet future obligations arising under the Company’s share schemes. It is expected that the Market Purchases will be funded by amounts advanced by the Company pursuant to a loan agreement dated the date hereof. The Trustee will make its trading decisions in relation to the Market Purchases independently of, and uninfluenced by, the Company.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW.
Mereo BioPharma Group plc("Mereo" or the "Company" or the "Group") LONDON, April 26, 2019 -- Mereo BioPharma Group plc (AIM: MPH) (NASDAQ: MREO), a clinical stage, UK-based,....
LONDON, April 24, 2019 -- Mereo BioPharma Group plc (AIM: MPH) (NASDAQ: MREO), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, today announces.